OneSource Specialty Pharma Ltd Company Fundamental Analysis

OneSource Specialty Pharma Ltd is a specialised contract development and manufacturing organisation (CDMO) that develops and manufactures complex pharmaceutical products for global drug companies. Its key business segments include biologics, sterile injectables, drug-device combinations and soft-gelatin capsules. The company is positioned to benefit from outsourcing by pharmaceutical companies and growing demand for complex injectable drugs, including GLP-1 medicines such as semaglutide. In Q1 FY27, consolidated revenue rose 37.2% year-on-year to ₹449 crore, while operating profit increased 39.1% to ₹119 crore. Net profit was ₹25 crore, compared with a small loss in the same quarter last year. However, depreciation of ₹71.75 crore and interest costs of ₹30.81 crore remained significant, reflecting the capital-intensive nature of the business. FY26 revenue was approximately ₹1,422 crore, but adjusted EBITDA margin declined to 21.4% from 32.3% in FY25. At the latest available market data, the company’s market capitalisation was around ₹16,000 crore, with a price-to-book ratio of roughly 2.7–2.8x. Its P/E ratio is difficult to interpret because earnings have been volatile and some data providers report very high trailing multiples. The stock’s potential drivers include semaglutide manufacturing, biologics, new customer contracts and improved plant utilisation. Key risks are high capital expenditure, interest and depreciation costs, regulatory requirements, execution delays and the possibility that growth falls short of expectations. Overall, OneSource has promising long-term CDMO opportunities, but profitability and cash-flow improvement need to validate its growth story. Its Q2 FY27 results are scheduled for 27 October 2026; the sources available for this analysis still show Q1 FY27 as the latest reported quarter, so Q2 performance should be checked once officially released.